Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 14 November 2017

Indication(s)

Vedrop is indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis, from birth (full term newborns) up to 18 years of age.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

+ 1 more

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Obesity

Obesity

Learn about the complex factors influencing development of obesity.

+ 4 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000920
Orphan designation No
Date First Approved 24-07-2009
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Orphan Europe S.A.R.L.
Warnings

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti